BridgeMD
New treatment option for Healthy Participants
Official title Fructose Intestinal Gluconeogenesis
ClinicalTrials.gov ID: NCT07209202
What this study is testing
- What it's testing
- This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 55. Healthy volunteers may be eligible.
You may be able to join if
- BMI 30 to 38 kg/m2 (obese group) or BMI 19 to 25 kg/m2 (lean group)
You likely can't join if
- Pregnancy or lactation within the past six months;
- Type 1 or 2 diabetes mellitus (including fasting glucose ≥126 mg/dL, HgbA1c ≥6.5%);
- History of liver disease or AST and ALT 2x above the upper limit of normal;
- Fasting triglyceride \> 300 mg/dl; total cholesterol levels above the 95th percentile for age and sex;
- Hemoglobin (Hgb) \<12.5g/d or hematocrit\<3x Hgb value;
- Report of HIV or hepatitis B or C infection;
See the full eligibility criteria
- BMI 30 to 38 kg/m2 (obese group) or BMI 19 to 25 kg/m2 (lean group)
- Pregnancy or lactation within the past six months;
- Type 1 or 2 diabetes mellitus (including fasting glucose ≥126 mg/dL, HgbA1c ≥6.5%);
- History of liver disease or AST and ALT 2x above the upper limit of normal;
- Fasting triglyceride \> 300 mg/dl; total cholesterol levels above the 95th percentile for age and sex;
- Hemoglobin (Hgb) \<12.5g/d or hematocrit\<3x Hgb value;
- Report of HIV or hepatitis B or C infection;
- History of cancer, other than basal cell or squamous cell carcinoma or kidney disease stage 3 or higher or patients currently on dialysis;
- Use of any anti-diabetic medications or hypolipidemic agents in the past six months;
- History of surgical procedure for obesity;
- Change in body weight \>5% in the past six months (by self-report);
- History of other conditions known to affect insulin sensitivity and lipid metabolism (e.g., polycystic ovary syndrome), history of galactosemia, hereditary fructose intolerance, or who test positive for fructose...
- Known intolerance to acetaminophen.
The study team makes the final eligibility decision.
Where it's taking place
- Vallejo, California, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 55 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Vallejo, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.